1,506
Participants
Start Date
December 14, 2019
Primary Completion Date
September 12, 2022
Study Completion Date
October 31, 2022
Lamivudine Oral Solution
In the intervention arm, HIV-1 negative children with HIV-1 positive mothers who have an HIV-1 viral load ≥ 1000 copies/ml will receive lamivudine syrup orally (7.5 mg twice daily if 2 to 4 kg; 25 mg twice a day if weight \<8 kg; and 50 mg twice a day if weight \>8 kg). The intervention will last a maximum of 10 months (until the baby is 12 months old or until the confirmed end of breastfeeding). Breastfeeding will be considered to be ceased if the mother confirms she is no longer breastfeeding for 2 consecutive monthly visits
CSPS and CMA of Do and Dafra districts, Bobo-Dioulasso
CSPS and CMA of Baskuy and Boulmiougou districts, Ouagadougou
Bauleni, Lusaka
Chaisa, Lusaka
Chilenje Level 1 hospital, Lusaka
Matero Main, Lusaka
University Teaching Hospital, Lusaka, Zambia
OTHER
Centre Muraz
OTHER
Institut National de la Santé Et de la Recherche Médicale, France
OTHER_GOV
University of Bergen
OTHER
ANRS, Emerging Infectious Diseases
OTHER_GOV